Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases
Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY)...
Ark Biopharma’s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years
Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China’s...
Hengrui’s HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates—HRS9531 (GLP‑1R/GIPR...
Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals
Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China’s...
Touchstone Medical Partners with INSPUR to Advance Healthcare AI and Medical Robots
Touchstone International Medical Science Co., Ltd. (SHA: 688013) announced a strategic partnership with INSPUR Co.,...
Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets
Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with...
Humanwell Healthcare’s HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its independently developed HW221043 tablets have...
Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...
Frontier Biotech’s FB7013 Wins NMPA IND for MASP‑2 siRNA in IgA Nephropathy
Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND)...
Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal
Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...
Kelun-Biotech’s sac-TMT Wins Breakthrough Therapy Designation for First‑Line NSCLC
Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac‑TMT, SKB264/MK‑2870), its TROP2‑directed...
Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology...
Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Investigational New Drug (IND) application...
Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China
Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly‑owned...
CMS Unveils BALANCE Model to Expand GLP-1 Access for Medicare/Medicaid
The U.S. Centers for Medicare & Medicaid Services (CMS) unveiled the BALANCE Model (Better Approaches...
GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy
GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...
Merck’s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world’s...
Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
Aspen Holdings announced a binding agreement for its wholly‑owned subsidiary Aspen Global Incorporated (AGI) to...
China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
The National Medical Products Administration (NMPA) announced that China approved 76 innovative drugs for marketing...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
Novo Nordisk (NYSE: NVO) announced that China’s Supreme People’s Court upheld the Beijing IP Court ruling,...